Image courtesy by QUE.com
The U.S. Food and Drug Administration on Monday ordered every maker of GLP-1 drugs to add a warning about a rare eye condition that can cause sudden, permanent vision loss. The move covers the biggest names in the booming weight-loss and diabetes market, including Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjaro and Zepbound, along with several older GLP-1 diabetes medicines, NBC News reported.
The timing is notable. The same morning, Lilly announced that its new once-daily GLP-1 pill, Foundayo, sharply reduced the severity of obstructive sleep apnea in a late-stage trial, according to CNBC. Taken together, the two headlines capture where this drug class stands right now: its list of approved uses keeps growing, and so does the attention regulators pay to its rare risks.
What the FDA Is Requiring
The condition is nonarteritic anterior ischemic optic neuropathy, or NAION. It happens when blood flow to the optic nerve, which carries signals from the eye to the brain, drops or is blocked. The result can be sudden, painless vision loss, usually in one eye. There is no known treatment, and the damage can be permanent.
According to NBC News, the FDA said there is "a potential increased risk of rare NAION" in people taking GLP-1 drugs, and that patients and caregivers should be aware of it. The agency said it reviewed reports sent to its adverse-event monitoring system and analyzed data from multiple clinical trials, and that NAION cases have been reported for all GLP-1 drugs now on the market. FDA scientists were not able to identify a mechanism that would explain how the drugs might raise the risk.
The FDA said its review began after a 2024 study in JAMA Ophthalmology found that diabetes patients prescribed semaglutide, the active ingredient in Ozempic and Wegovy, were four times as likely to develop NAION as those not prescribed the drug. Spokespeople for Novo Nordisk and Lilly told NBC News that patient safety is their top priority, and Lilly said it was aware of studies on a possible link.
How Rare Is It?
Very rare. NAION is the second most common optic nerve disease in the U.S., but it affects up to 10 out of every 100,000 people over age 50, according to the American Academy of Ophthalmology figures cited by NBC News. Its risk factors also overlap heavily with the conditions GLP-1 drugs are prescribed for, including Type 2 diabetes, obesity, sleep apnea and high blood pressure. That overlap is one reason it has been hard to tell whether the drugs cause the problem or whether the people taking them were already at higher risk.
Dr. Manjot Gill, an ophthalmologist at Northwestern Medicine, told NBC News the label change was appropriate but cautioned against panic. She said patients should not stop their medications out of anxiety, and that the main value of the warning is awareness: anyone who notices a change in their vision should see an eye doctor promptly.
The new warning joins others already on GLP-1 labels, including pancreatitis, gallbladder problems and kidney injury, plus a boxed warning, the FDA's strongest, about a possible risk of thyroid tumors.
Meanwhile, the Use Cases Keep Expanding
Lilly's Foundayo, which launched in the U.S. in April, met its main goal in a late-stage sleep apnea study, CNBC reported. Among participants not using a PAP machine, those on the pill had an average of 21.1 fewer breathing interruptions per hour after 52 weeks, compared with 4.8 fewer on placebo, an overall reduction of 43.8% versus 6.3%. Lilly said 31.5% of that group reached remission or improved to mild sleep apnea. In patients also using PAP therapy, Foundayo cut events by 18.3 per hour versus 5.5 for placebo. Lilly plans to file for U.S. approval in moderate-to-severe obstructive sleep apnea by the end of the year.
A pill matters commercially because it removes the injection barrier and can be easier to manufacture and ship at scale. A sleep apnea label would also widen the pool of patients a doctor can justify treating, which matters for insurance coverage.
Why It Matters for Business
For drugmakers and investors, a class-wide label change is less damaging than a warning aimed at one product, because it doesn't hand any competitor an edge. The bigger question is whether the warning slows prescribing among cautious doctors or patients, especially for people who take GLP-1s purely for weight loss rather than diabetes. Every new indication, like sleep apnea, strengthens the benefit side of that calculation.
For employers and health plans, which already spend heavily on these drugs, the warning adds a monitoring cost. Expect more emphasis on baseline eye exams for higher-risk members and on clear guidance telling patients what symptoms to report. Benefit managers weighing whether to cover GLP-1s for obesity will add this to their risk review, but given how rare NAION is, it is unlikely to change coverage decisions on its own.
For telehealth platforms and clinics that prescribe GLP-1s at high volume, the practical steps are straightforward: update patient education and consent materials, ask about vision changes at follow-up visits, and make sure patients know where to go if their sight suddenly changes. Clinics that communicate this well build trust, and trust is what keeps patients on long-term therapy.
What Patients Should Do
Doctors quoted by NBC News were clear that the warning is not a reason to stop treatment without medical advice. People on GLP-1 drugs should know the main symptom, sudden painless loss of vision in one eye, and get to an eye care provider right away if it happens. Anyone with several NAION risk factors may want to talk with their doctor about whether an eye exam makes sense.
The Bottom Line
Monday's news shows both sides of the GLP-1 story. The drugs keep proving useful for more conditions, and Lilly's pill could soon add sleep apnea to the list. At the same time, as tens of millions of people take them, rare side effects become visible and regulators act on them. For the industry, the job now is to keep growing while being open about those risks.
Never miss a patient call. Clinics and telehealth providers fielding a wave of questions about medication safety can let MAJ.COM Voice AI answer every inbound call 24/7 and handle outbound follow-ups and support, so no patient or lead goes unanswered.
Edited by Coron @QUE.COM
Website: https://QUE.COM Intelligence
Sponsored by: https://MAJ.COM AI Autonomous
Articles published by QUE.COM Intelligence via Yehey.com website.
0 Comments